Revenue
2010
2011
2022
2023
2024
2025
Theriva Biologics, Inc. (TOVX)
Price—Loading quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | $0 | $2.6M |
| Research & development | $8.6M | $12.0M | $14.3M | $11.7M | $7.8M | $5.1M | $11.1M | $11.8M | $18.8M | $29.1M | $32.9M | $14.5M | $6.5M | $12.3M | $3.3M | $1.6M |
| Operating expenses | $24.1M | $26.3M | $21.4M | $21.6M | $14.3M | $10.2M | $15.7M | $17.6M | $26.3M | $39.3M | $41.0M | $20.5M | $12.3M | $17.3M | $5.9M | $3.7M |
| Operating income | −$24.1M | −$26.3M | −$21.4M | −$21.6M | −$14.3M | −$10.2M | −$15.7M | −$17.6M | −$26.3M | −$39.3M | −$41.0M | −$20.5M | −$12.3M | −$17.3M | — | — |
| EBITDA | −$23.9M | −$26.2M | −$21.3M | −$21.5M | −$14.2M | −$10.0M | −$15.4M | −$17.3M | −$26.0M | −$39.1M | −$40.9M | −$20.5M | −$12.3M | −$17.2M | — | — |
| Net income | −$23.7M | −$25.7M | −$18.3M | −$19.7M | −$14.3M | −$10.0M | −$15.3M | −$13.4M | −$15.2M | −$27.3M | −$43.7M | −$19.8M | −$12.3M | −$17.1M | −$8.1M | −$1.7M |
| Net profit margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | −65.46% |
| Basic EPSper basic share | -$2.08 | -$19.03 | -$28.48 | -$32.75 | -$47.50 | -$16.50 | -$24.50 | -$101.50 | -$155.75 | -$232.00 | -$432.00 | -$256.00 | -$216.00 | -$392.00 | -$232.00 | -$64.00 |
| Diluted EPSper diluted share | -$2.08 | -$19.03 | -$28.48 | -$32.75 | -$47.50 | -$16.50 | -$24.50 | -$101.50 | -$155.75 | -$232.00 | -$432.00 | -$256.00 | -$216.00 | -$392.00 | -$232.00 | -$64.00 |
Owners
Reported shareholders
1.06%of listed shares
VANGUARD CAPITAL MANAGEMENT LLC486.18K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
VANGUARD CAPITAL MANAGEMENT LLC | 1.06%486.18K shares |
JANE STREET GROUP, LLC | 0.72%331.92K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.64%294.02K shares |
VANGUARD FIDUCIARY TRUST CO | 0.53%241.78K shares |
Ikarian Capital, LLC | 0.24%112.08K shares |
Virtu Financial LLC | 0.19%87.14K shares |
NORTHERN TRUST CORP | 0.18%82.7K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.14%63.71K shares |
UBS Group AG | 0.13%61.05K shares |
XTX Topco Ltd | 0.12%53.87K shares |
Ground Swell Capital, LLC | 0.08%35.29K shares |
BOOTHBAY FUND MANAGEMENT, LLC | 0.06%27.65K shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.05%24.06K shares |
MORGAN STANLEY | 0.04%20.3K shares |
TWO SIGMA SECURITIES, LLC | 0.04%19.75K shares |
TWO SIGMA INVESTMENTS, LP | 0.03%15.46K shares |
SCHWARZ DYGOS WHEELER INVESTMENT ADVISORS LLC | 0.03%15K shares |
BlackRock, Inc. | 0.02%7.5K shares |
OSAIC HOLDINGS, INC. | <0.01%441 shares |
SBI Securities Co., Ltd. | <0.01%358 shares |
Percentages use 45.89M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data